These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 34366407

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
    Karyağar S, Güven O, Karyağar SS, Arici S, Selvi O, Geredeli Ç, Özülker F.
    Nucl Med Commun; 2021 Sep 01; 42(9):1011-1016. PubMed ID: 33958536
    [Abstract] [Full Text] [Related]

  • 4. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients.
    Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H.
    Ann Nucl Med; 2021 May 01; 35(5):540-548. PubMed ID: 33586097
    [Abstract] [Full Text] [Related]

  • 5. Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study.
    Wibmer AG, Morris MJ, Gonen M, Zheng J, Hricak H, Larson S, Scher HI, Vargas HA.
    J Nucl Med; 2021 Aug 01; 62(8):1050-1056. PubMed ID: 33419944
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
    Plouznikoff N, Artigas C, Sideris S, Martinez Chanza N, Gil T, Peltier A, Flamen P.
    Ann Nucl Med; 2019 Dec 01; 33(12):945-954. PubMed ID: 31587172
    [Abstract] [Full Text] [Related]

  • 9. Prediction of early biochemical response after 177Lu-PSMA radioligand therapy with 68Ga-PSMA PET, a different perspective with quantitative parameters.
    Aksu A, Vural Topuz Ö, Yilmaz B, Karahan Şen NP, Acar E, Çapa Kaya G.
    Nucl Med Commun; 2022 Apr 01; 43(4):468-474. PubMed ID: 35045552
    [Abstract] [Full Text] [Related]

  • 10. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L, Subramaniam S, Joshua AM, Crumbaker M, Martin A, Zhang AY, Rana N, Langford A, Mitchell J, Yip S, Francis R, Hofman MS, Sandhu S, Azad A, Gedye C, McJannett M, Stockler MR, Davis ID, Australian, New Zealand Urogenital, Prostate Cancer Trials Group (ANZUP), the ENZA-p investigators.
    BJU Int; 2021 Nov 01; 128(5):642-651. PubMed ID: 34028967
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
    Okudan B, Coşkun N, Seven B, Atalay MA, Yildirim A, Görtan FA.
    Nucl Med Commun; 2021 Nov 01; 42(11):1254-1260. PubMed ID: 34284438
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.
    Singh B, Sharma S, Bansal P, Hooda M, Singh H, Parihar AS, Kumar A, Watts A, Mohan R, Singh SK.
    Nucl Med Commun; 2021 May 01; 42(5):482-489. PubMed ID: 33395191
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.
    Emmett L, Yin C, Crumbaker M, Hruby G, Kneebone A, Epstein R, Nguyen Q, Hickey A, Ihsheish N, O'Neill G, Horvath L, Chalasani V, Stricker P, Joshua AM.
    J Nucl Med; 2019 Jul 01; 60(7):950-954. PubMed ID: 30552200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.